<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115593</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-Hystocor</org_study_id>
    <nct_id>NCT03115593</nct_id>
  </id_info>
  <brief_title>Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer</brief_title>
  <official_title>Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrial cancer is the most common pelvic gynecological cancer in so-called developed
      countries, with 320,000 new cases annually, including more than 1,500 in Belgium. It
      preferentially affects postmenopausal women. Overall survival at 5 years is 76% but is 95%
      for early forms, which represent more than 70% of diagnoses. The main risk factors are
      obesity, diabetes and tamoxifen intake for breast cancer, which explains the increasing
      incidence. Half a million new annual cases are expected in 2035.

      The main symptom is postmenopausal metrorrhagia.Among these women, the prevalence of the
      disease is estimated between 10 and 15%. Currently the recommendations are to make an
      evaluation by endovaginal ultrasound followed by an endometrial biopsy. The histological type
      is the main predictor of the severity of the disease and acts as guideline for the
      treatment.It is therefore essential to have precise biopsy results before starting
      therapeutic management.

      The most widely used technique is the blind biopsy by aspiration using a pipette because it
      is inexpensive, easy, without any specific equipment. However, recent studies showed that
      this technique has a poor sensitivity in the target population of postmenopausal women. Other
      studies have shown that targeted biopsies under hysteroscopic control could have a much
      higher sensitivity.

      The main objective of this study is thus to compare the performance of the targeted biopsy
      under hysteroscopy to the performance of the biopsy by aspiration with a pipette, for the
      diagnosis of endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological result</measure>
    <time_frame>6 months</time_frame>
    <description>Histological result (histological type and grading if cancer is diagnosed, according to the FIGO 2009 classification).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>postmenopausal patients with metrorrhagia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).
The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blind biopsy with a pipette</intervention_name>
    <description>Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.</description>
    <arm_group_label>postmenopausal patients with metrorrhagia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted biopsy using hysteroscopy</intervention_name>
    <description>During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.</description>
    <arm_group_label>postmenopausal patients with metrorrhagia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal patient.

          -  patient with postmenopausal metrorrhagia and endometrial hypertrophy defined by an
             endometrium ticker than 3 mm (ultrasound result)

        Exclusion Criteria:

          -  patients undergoing hormone replacement therapy for menopause (THM). This treatment
             may be the cause of benign bleeding in post menopause.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Nazac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>André Nazac, MD</last_name>
    <phone>32 2 4772660</phone>
    <email>Andre.NAZAC@chu-brugmann.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André Nazac, MD</last_name>
      <phone>32 2 4772660</phone>
      <email>Andre.NAZAC@chu-brugmann.be</email>
    </contact>
    <investigator>
      <last_name>André Nazac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Iris Sud - Site Ixelles</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric Buxant, MD</last_name>
      <phone>00 32 2 739 85 85</phone>
      <email>fbuxant@his-izz.be</email>
    </contact>
    <investigator>
      <last_name>Frédéric Buxant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent de Landsheere, MD</last_name>
      <phone>00 32 4 321 65 15</phone>
      <email>ldelandsheere@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Laurent de Landsheere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé Fernandez, MD</last_name>
      <phone>01-45-21-77-01</phone>
      <email>herve.fernandez@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Andre Nazac</investigator_full_name>
    <investigator_title>Head of clinic</investigator_title>
  </responsible_party>
  <keyword>hysteroscopy</keyword>
  <keyword>pipette</keyword>
  <keyword>biopsy</keyword>
  <keyword>endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

